DESIGN, SETTING AND PARTICIPANTS:
Longitudinal observational study of non-institutionalized Medicare beneficiaries aged 65 and older (n=9,573) employing administrative data from the Centers for Medicare and Medicaid Services (CMS) and survey-based data from beneficiaries (2003, 2006) . Sampling drew from a 1% national probability sample (2003) , oversampling lowincome beneficiaries including those dually-enrolled in Medicare and Medicaid.
MEASUREMENTS & MAIN RESULTS:
Number and type of prescriptions, monthly out-of-pocket prescription spending, and cost-related non-adherence to prescription regimens. Most respondents who lacked prescription coverage in 2003 had acquired it by 2006 (82.6%)-primarily through Part D (63.1%). Part D enrollees who previously lacked coverage or had Medigap coverage appear particularly advantaged by Part D, as evidenced by significantly increased prescription use, lower out-of-pocket spending and lower nonadherence. Those with employer-based coverage experienced significantly increased spending. Among those still lacking coverage in 2006, high rates of cost-related non-adherence (31.8%) were reported by the lowincome, chronically ill subgroup.
CONCLUSIONS:
In its first year, Part D coverage appears to have moderated prescription spending and cost-related burden for those who previously had meager benefits or none. Increased spending among those with employer-based coverage may reflect a narrowing of those benefits over this period. Evidence of foregone care among low-income, chronically ill seniors who still lack prescription coverage highlights
INTRODUCTION
The introduction of the Medicare prescription drug benefit represents the largest expansion of Medicare benefits since the program's inception in 1966. In January 2006, 43 million Medicare beneficiaries became eligible for subsidized prescription coverage through Medicare Part D. To obtain the coverage, beneficiaries could enroll in either a stand-alone prescription drug plan (PDP) or a Medicare Advantage Prescription Drug plan (MA-PD). The program aimed to reduce the number of beneficiaries without prescription coverage and make prescription drugs more affordable for Medicare beneficiaries. The importance of doing so, in the face of the increasing financial burden associated with prescription medicines, has been well documented [1] [2] [3] [4] [5] .
By the end of 2006, more than half of all Medicare beneficiaries (22.5 million) were enrolled in a Part D plan, according to the Centers for Medicare and Medicaid Services (CMS) 6 . Of these, 8.6 million were receiving additional assistance through the low-income subsidy program (LIS). Most LIS enrollees (6.3 million) transitioned from Medicaid, as required by law, but others applied directly and were deemed eligible (2.3 million). Another 15 million beneficiaries (34%) had other sources of comparable prescription coverage ("creditable coverage"), mainly through employer-sponsored plans 6 . Thus, by the end of 2006, nearly 90% of all Medicare beneficiaries reportedly had Part D or another source of prescription coverage, while only three years earlier, about one-quarter of seniors reported no prescription drug coverage 3 .
To date, several studies have employed claims data from large pharmacy chains to evaluate changes in prescription use and out-of-pocket spending among Part D enrollees [7] [8] [9] , one study reported early experiences of Part D enrollees 10, 11 , and one study reported population-level changes in medication non-adherence before and after Part D implementation 11 , However, to our knowledge, no study has afforded longitudinal information on the specific cover- Non-Adherence. Cost-related non-adherence was evaluated with previously validated questions about the following behaviors: (i) not filling a prescription because of cost; (ii) taking smaller doses to make a prescription last longer; (iii) skipping doses to make a prescription last longer. These items have been shown to produce reliable, stable and valid estimates of cost-related medication non-adherence and were incorporated into the MCBS in 2004 Probability sampling weights were applied to all analyses to correct for unequal sampling probabilities across states and strata. The statistical software used (STATA 7.0) takes these weights into account when computing standard errors. . This is consistent with employer surveys conducted around the time of Part D implementation, which found the vast majority of employers intending to continue supporting prescription drug coverage 17 , though many significantly increased cost-sharing requirements 18 .
RESULTS

Transitions in Prescription Coverage
Sociodemographic and Health Profiles of Prescription
Coverage Subgroups. Compared with those in Part D plans in 2006 (n = 5171), those who retained employer-based prescription plans (n=1882) were younger, disproportionately white, and had more education, higher incomes, and fewer chronic conditions (p<0.001) ( Table 2) . Those who transitioned from employer-based prescription plans to Part D (n=649) were significantly more likely to be of minority race/ethnicity, lower income, and to be somewhat sicker (i.e., more chronic conditions, higher prescription medication use) than those retaining employer coverage (p<0.05). Similarly, those who remained without prescription coverage throughout the study period (n=476) appear healthier than those who transitioned from no coverage into a Part D (Table 3) . Increased use was statistically significant for those who transitioned to Part D from no coverage and from Medigap (unadjusted and adjusted models, p<0.001).
All Part D subgroups, except those previously reporting employer-based coverage, reported lower out-of-pocket spending in 2006 than 2003. In adjusted models, the odds of spending more than $100 per month on prescriptions were significantly reduced for Part D enrollees who previously lacked coverage (OR=0.3, p<0.001). Those who transitioned from Medicaid drug coverage also showed significantly reduced odds of spending more than $100 per month (OR=0.5, p<0.05) and more than $300 per month (OR=−6.2, p<0.01).
Those (Table 5 ). They appear significantly less engaged with the health care system overallless likely to have a primary care physician (p<0.001), to have seen any physicians in the past year (p<0.001) or to take any medications (p<0.001). While some of this may be attributable to their relatively good health, subgroup analyses reveal important distinctions. The largest subgroup of those persistently without drug coverage are low-income, chronically ill seniors (n=170), who show significant financial strain related to health care. Within this subgroup, nearly one-quarter report having forgone physician care in the past year due to cost (22.1%, p<0.001) and 9.9% reporting that they did not seek hospital care when needed due to concern about the associated out-of-pocket costs (p<0.01). This subgroup is significantly more likely than the overall sample to spend more than $100 per month on prescriptions (38.0%, p<0.05) and to report costrelated non-adherence (31.8%, p<0.001). While the potential value of financial assistance with prescription costs is apparent for this subgroup, few report having applied for the Part D low- Seniors Who Continue To Lack Prescription Coverage. Finally, our findings evidence two relatively distinct groups of seniors who remained without prescription coverage throughout the 3-year study period. The first are seniors who appear to have made a considered decision to remain without prescription coverage. Of these, some are low-income seniors who report no chronic conditions, and who appear to be largely detached from the health care system. Others are higher income seniors Respondents either chose the "Other" option for not applying (n=452) or did not specify a reason for not applying (n=264).
with or without chronic conditions, but evidencing little financial burden related to their health care needs. By contrast, the second group of seniors who persistently lacked drug coverage are both low income and chronically ill, and show evidence of considerable financial strain related to health care overall and prescription medications, specifically. The majority of these seniors was unaware of LIS assistance or believed they were ineligible, underscoring the value of aggressive, targeted and continuing outreach for LIS enrollment.
Limitations. The study has several relevant limitations. First, while the longitudinal design affords a unique opportunity to evaluate changes in prescription use and spending associated with changes in coverage, those who are sickest and most disengaged from the system are more likely to be unrepresented due to non-response or study attrition. In addition, the study design excluded institutionalized beneficiaries and those younger than age 65. The high poverty and disease burden of both groups press for evaluating their experiences over time. Next, the study relies entirely on selfreported information concerning prescription coverage status, sources, use and spending. The longitudinal design, wherein each individual serves as his own control, helps mitigate any systematic biases in self-reported information. However, claims data, if available, would be advantageous. Finally, without information about the specific prescription medications used over time, the study has limited ability to comment on the observed changes from a clinical perspective. The study findings complement several recent studies that employ pharmacy claims data that, while applied to more limited sample frames than this study, find comparable utilization and spending trends [7] [8] [9] , and afford clinically relevant information about drug-specific utilization changes 8, 9 .
CONCLUSIONS
Evidence of Medicare beneficiaries' early experiences with Part D is largely favorable. Since 2003, the share of seniors who lacked prescription coverage declined substantially, and those enrolled in Part D plans who previously lacked coverage or had meager benefits now appear better able to afford their prescription medications-with significantly higher use rates, lower out-of-pocket costs and reduced cost-related non-adherence. However, the findings evidence an erosion of employersponsored drug coverage, documenting for the first time this group's changes in out-of-pocket spending over the period surrounding Part D implementation. This finding, coupled with evidence of unfavorable selection of sicker, more socioeconomically disadvantaged beneficiaries from employer-sponsored plans into Part D has important implications for the program's future, and merits continued monitoring. Finally, nearly one in ten non-institutionalized beneficiaries lacked prescription coverage in 2006, and it appears that about one-third of these are low-income, chronically ill seniors who evidence considerable difficulty affording their medicines. Aggressive, targeted outreach to this group for LIS enrollment remains important. Ongoing monitoring of the program overall, and the experiences of its enrollees, will remain important with the continued evolution of Part D benefits, and of the plans and markets through which they are delivered.
